Startups
Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity.
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity.
Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
Overview
Location
Sweden, Södertälje
Employees
51-200
Total raised
$156.8M
Founded date
2014
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 31, 2023 | Funding round | $36.69M | |
| Dec 22, 2022 | Funding round | $26.55M | |
| Jul 22, 2021 | Series B round | $47.56M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 11, 2026 | Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer | Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple clinical sites with ANOC-001, a novel T ce... |
| Aug 19, 2025 | Anocca Raises Approx. USD46M in Funding | Anocca, a Södertälje, Sweden-based clinical-stage T-cell immunotherapy company, has successfully raised USD ~46M in financing. The round was led by Mellby Gård with participation from AMF, Ramsbury and existing shareholders, alongside new i... |
| Nov 26, 2024 | Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer | Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer Tue, Nov 26, 2024 09:00 CET Report this content Application to the European Medicines Agency (EMA) covers ANOC-001 as the ... |
| May 30, 2024 | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology | Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology Thu, May 30, 2024 12:00 CET Report this content Södertälje, Sweden, & San Francisco, USA and Kyoto, Japan, 30 May 2... |
| May 31, 2023 | Anocca Raises USD36.58M in Equity Funding | Anocca AB, a Södertälje, Sweden-based developer of cancer cell therapies, raised SEK 400m (approx. USD36.58M) in equity financing. The round was led by AMF and Mellby Gård, with participation from Michano, Swedbank Robur, Ramsbury, Nidoco a... |
| May 31, 2023 | Anocca raises SEK 400 million for large-scale development of cancer cell therapies | |
| Dec 22, 2022 | Sweden-based Anocca secures €25M from EIB to develop T-cell therapies for cancer | Södertälje-based Anocca, a fully integrated cell therapy biotechnology company, announced on Wednesday, December 21, that it has raised €25M in venture debt funding from the European Investment Bank (EIB). Paolo Gentiloni, European Commissi... |
| Dec 21, 2022 | Anocca Secures EUR 25M from the European Investment Bank | Anocca, a Södertälje, Sweden-based cell therapy biotechnology company, received €25M in Venture Debt. The European Investment Bank made the financing. The company intends to use the funds to move T-cell immunotherapies towards clinical tria... |
| Aug 2, 2021 | Sweden’s Anocca raises €40M to develop novel therapeutics for cancer, infectious disease, autoimmunity | T-Cells are crucial immune cells capable of recognising cancers over healthy cells. Utilising the immune system to recognise and destroy tumour cells has been the primary goal of anti-cancer immunotherapy. Recently, there has been an increa... |
Show more
Reviews 0
FAQ about Anocca AB
When was Anocca AB founded?
Anocca AB was founded in 2014.
How much funding has Anocca AB raised?
Anocca AB has raised $156.8M in total across 4 funding rounds.
What funding rounds has Anocca AB raised?
Parsers VC lists 4 funding rounds of Anocca AB, among them a funding round of $36.69M on May 31, 2023, a funding round of $26.55M on Dec 22, 2022 and a Series B round of $47.56M on Jul 22, 2021.
What has the press written about Anocca AB?
Parsers VC has collected 14 articles mentioning Anocca AB, among them “Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer” (Jun 11, 2026) and “Anocca Raises Approx. USD46M in Funding” (Aug 19, 2025).
Is Anocca AB still active?
Yes, Anocca AB is active; its latest activity on Parsers VC dates from Aug 27, 2026.